<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/743B0403-114A-4062-A04B-26B6E57DE502"><gtr:id>743B0403-114A-4062-A04B-26B6E57DE502</gtr:id><gtr:name>Columbia University</gtr:name><gtr:address><gtr:line1>Columbia University</gtr:line1><gtr:line2>2960 Broadway</gtr:line2><gtr:line4>New York</gtr:line4><gtr:line5>NY 10027-6902</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/743B0403-114A-4062-A04B-26B6E57DE502"><gtr:id>743B0403-114A-4062-A04B-26B6E57DE502</gtr:id><gtr:name>Columbia University</gtr:name><gtr:address><gtr:line1>Columbia University</gtr:line1><gtr:line2>2960 Broadway</gtr:line2><gtr:line4>New York</gtr:line4><gtr:line5>NY 10027-6902</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7F2E367C-4AE6-460F-8127-BDF28582EC83"><gtr:id>7F2E367C-4AE6-460F-8127-BDF28582EC83</gtr:id><gtr:firstName>Marc</gtr:firstName><gtr:surname>Mansour</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500389"><gtr:id>6F3AB528-2F13-4746-BD0B-1EF983DBB502</gtr:id><gtr:title>Role of the Notch signalling pathway in acute myeloid leukaemia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500389</gtr:grantReference><gtr:abstractText>We are trying to identify the role that a gene called Notch plays in acute leukaemia. We already know that over half of children with T-cell acute lymphoblastic leukaemia (T-ALL) have mutations in Notch-1, but their role in the causation of the disease is not completely understood. 

The Notch pathway plays several roles in normal blood cell production, being particularly important in the production of T-cells and blood stem cells. 

Leukaemic cells are unable to develop into normal blood cells. Our preliminary studies suggest that a gene called CSL, which binds to Notch, may prevent normal cell development. By inserting this gene into normal and leukaemic cells in culture, we hope to gain an understanding as to how, and why, this might be the case. We will also explore the possibility that other members of the Notch family are involved in leukaemia development.
We are particularly interested in addressing whether Notch-1 mutations occur in all age groups of patients with T-ALL and whether they are involved in other forms of acute leukaemia apart from T-ALL. This is particularly timely as drugs that inhibit Notch are in development for the treatment of T-ALL. 
.</gtr:abstractText><gtr:technicalSummary>The Notch pathway, pivotal in directing cell fate in embryonic development, is now recognised as having an important role in regulation of haemopoiesis. Notch directs the transition from common lymphoid stem cell to committed T-cell progenitor, and has recently been shown to regulate the stem cell niche, affect myeloid differentiation, and control haemopoietic stem cell self-renewal, all of which are dysregulated in leukaemogenesis. It is a membrane-bound receptor; on ligand binding its intracellular portion is cleaved and translocates to the nucleus to bind the transcription factor CSL. It has recently been discovered that &amp;gt;50% of paediatric/adolescent patients with T-cell acute lymphoblastic leukaemia (T-ALL) have activating mutations in the Notch-1 receptor in either the heterodimerisation or PEST domain, and sometimes in both domains. Notch-3, which shares many features with Notch-1, including its ability to produce a T-cell leukaemia on transfection into mice, is a likely target gene in those cases of T-ALL without a Notch-1 mutation. We hypothesise that mutations of the Notch pathway may be found in acute myeloid leukaemia (AML) patients where there is aberrant T-cell expression. Infants with leukaemia often have mixed lineage surface antigen expression and this rare group of patients also warrants detailed analysis. Additionally, we have found that ?50% of patients with AML have a previously undescribed isoform of CSL where exon 10 is truncated (termed CSL-TREX). When AML blasts can be induced to differentiate in vitro, CSL-TREX is down-regulated, thus raising the possibility that it contributes to maintenance of the undifferentiated state in vivo.

Samples from a cohort of infant leukaemia patients, accessed from the UCL Institute of Child Health DNA bank, will be screened for Notch-1 and Notch-3 mutations by heteroduplex analysis, and positive samples sequenced. Notch-1 will be studied in 50 adult AML patients with aberrant T-cell expression and comparedwith 50 patients without these markers, as identified from the MRC DNA bank. In order to explore the possibility of autocrine stimulation, the Notch ligand Jagged-1, Notch-1 and the downstream molecule HES-1, will be quantified by real-time RT-PCR of 200 AML RNA samples. We will use a single cell, Notch-sensitive, GFP-reporter system to analyse Notch activation in de novo AML cells. Finally, we will further characterise the function of CSL-TREX by transfecting CD34+ cells using a GFP-expressing lentiviral vector. These studies are particularly timely as -secretase inhibitors that inhibit Notch function are already in phase I/II trials in childhood T-ALL.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>211866</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pediatric Oncology</gtr:department><gtr:description>CSL isoform characterisation</gtr:description><gtr:id>31DEDF06-A408-4090-8398-3D47C0F494DD</gtr:id><gtr:impact>Now have adequate data to publish. Plan to submit to JEM</gtr:impact><gtr:outcomeId>f3QF4Z7kxCg-1</gtr:outcomeId><gtr:partnerContribution>Novel isoform of CSL has been tested in vivo at DFCI</gtr:partnerContribution><gtr:piContribution>Identified a novel isoform of CSL</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Columbia University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Adolfo Ferrando group</gtr:description><gtr:id>422FAB1D-F1F4-4DFB-9E66-0928EBC64147</gtr:id><gtr:impact>This resulted in two publications: PubMedID 19494353 and 19635999</gtr:impact><gtr:outcomeId>EB7174DCD9B-1</gtr:outcomeId><gtr:partnerContribution>Added data on 34 patients to our 54 patients treated on the same trial.</gtr:partnerContribution><gtr:piContribution>DNA samples from the ECOG2993/MRC UKALLXII trial for acute lymphoblastic leukaemia were never prospectively collected or stored. I collected 54 samples of UK treated ALL patients from the trial and analysed Notch and FBXW7 mutation status. We collaborated with Adolfo Ferrando's group from Columbia University, New York, who had data on 34 patients treated on the same trial enabling us to combine the data for meaningful statistical analysis of prognostic outcome.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brigham and Women's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>CSL</gtr:description><gtr:id>EB269ECE-280C-4F38-B157-B1884F4BB846</gtr:id><gtr:impact>Now have enough data from our combined studies to submit for publication. Aiming for submission to JEM.</gtr:impact><gtr:outcomeId>mW7rdjPRF9E-1</gtr:outcomeId><gtr:partnerContribution>Performing biochemical analysis of the CSL interacting partners</gtr:partnerContribution><gtr:piContribution>We identified a novel isoform of CSL which Jon Aster's group is helping us characterise</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brigham and Women's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Stephen Blacklow Group</gtr:description><gtr:id>84AB1D4C-D07C-448B-B3A8-57EB1497DC5E</gtr:id><gtr:impact>Publication Pubmed ID 19075186</gtr:impact><gtr:outcomeId>C7F5A49C507-1</gtr:outcomeId><gtr:partnerContribution>Blacklow's group solved the crystal structure of Notch-1 enabling our novel mutation to be structurally and functionally analysed.</gtr:partnerContribution><gtr:piContribution>We identified an activating mutation in the LNR domain, the first ever to be reported in this domain of Notch-1, in a patient with T-ALL. Blacklow and Aster's group solved the crystal structure of Notch-1 and by mapping our novel mutation, were able to make important predictions on functionality of the LNR domain in terms of Notch activation.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>CRUK Fundraisers</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>F9FF056B-D674-44BF-B8FB-7CA3D6314371</gtr:id><gtr:impact>Fundraisers (Dallaglio Foundation) for CRUK were interested in what was involved in a Clinical Research Training Fellowship and the research outcome from my work.

The Dellaglio Foundation managed to raise &amp;pound;650,000 specifically for Clinical Research Training Fellowships for CRUK</gtr:impact><gtr:outcomeId>4437FFFF1AB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>570000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF Intermediate Fellowship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>1AE18903-03CD-4ABF-B03A-750E3CCA381E</gtr:id><gtr:outcomeId>A498A373B580</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in American Society of Hematology Educational Review on T-ALL</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>FB924377-F641-459B-BC97-DA8E18D02BDA</gtr:id><gtr:impact>Identification of Notch1 mutations as secondary events rather than initiating events and are unstable with disease relapse suggests they should not be used as markers for minimal residual disease analysis in disease prognostication</gtr:impact><gtr:outcomeId>gCjWuw7JgKj</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>DNA samples were never collected prospectively on the UK MRC UKALLXII trial, despite patients consenting to collection and molecular analysis at the time of trial entry. By contacting sites around the country, I collected 54 diagnostic DNA samples from patients with T-ALL, all uniformly treated on the trial. Correlation of molecular abnormalities with prognostic outcome and clinical variables in this rare disease is now possible.</gtr:description><gtr:id>519C7200-9CB8-45DF-8CAF-19369BC85808</gtr:id><gtr:impact>Together with the 34 patients collected by our collaborators from ECOG (joint trial), we have one of the largest collection of adult T-ALL samples treated on the same trial. This has led to two notable publications : PMID: 19494353 and PMID: 19635999.</gtr:impact><gtr:outcomeId>E00CC89A568</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>T-ALL sample bank</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19494353</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>69652007-331C-4F1F-9A12-1D79AD23E19D</gtr:id><gtr:title>High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f5854a0f05a4b6cbb8bd46638e73647"><gtr:id>9f5854a0f05a4b6cbb8bd46638e73647</gtr:id><gtr:otherNames>Mansour MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>D3467F69F41</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62678E8E-4672-4ED8-BC31-164EC106756B</gtr:id><gtr:title>Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f5854a0f05a4b6cbb8bd46638e73647"><gtr:id>9f5854a0f05a4b6cbb8bd46638e73647</gtr:id><gtr:otherNames>Mansour MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>F4E5BA99ACD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B07B1AAE-33C8-48E6-8B47-FF7242D5EB02</gtr:id><gtr:title>Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f5854a0f05a4b6cbb8bd46638e73647"><gtr:id>9f5854a0f05a4b6cbb8bd46638e73647</gtr:id><gtr:otherNames>Mansour MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>538380B1925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B477836C-FED8-4902-804C-57730BBD72F4</gtr:id><gtr:title>Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19f64f5de0e3cd73f6dbe3881791ab30"><gtr:id>19f64f5de0e3cd73f6dbe3881791ab30</gtr:id><gtr:otherNames>Maser RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>458AD072CAD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8646F99F-C259-4152-B4F2-B890E2AA0F43</gtr:id><gtr:title>WT1 mutations in T-ALL.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c050ebd0939bd2b0d742c7262e3ec1a0"><gtr:id>c050ebd0939bd2b0d742c7262e3ec1a0</gtr:id><gtr:otherNames>Tosello V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>A97093D7450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF61C5E7-43AF-408A-9C52-673D01FF522E</gtr:id><gtr:title>Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e770a995fe961ec576df7ed546e2e990"><gtr:id>e770a995fe961ec576df7ed546e2e990</gtr:id><gtr:otherNames>Gordon WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>BE12544DC04</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EE9CDA9-C9C6-4BDD-AF2D-CB548CA2066C</gtr:id><gtr:title>Notch signaling: switching an oncogene to a tumor suppressor.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f6b48614ed9e24fa39dd250ba9b8b4f"><gtr:id>2f6b48614ed9e24fa39dd250ba9b8b4f</gtr:id><gtr:otherNames>Lobry C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5464cc8f1bc6b3.05918345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>822223EC-4F95-4D32-99EC-D8695CF99547</gtr:id><gtr:title>Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ebfedddf7f438d6eab0064b9415c177"><gtr:id>4ebfedddf7f438d6eab0064b9415c177</gtr:id><gtr:otherNames>Howe SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>D9AD1543AAC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0006B99C-D2AF-4931-8149-6CB81D866FB6</gtr:id><gtr:title>Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd8512582a2495e8042a388a114ad30"><gtr:id>acd8512582a2495e8042a388a114ad30</gtr:id><gtr:otherNames>Jenkinson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_16221_21_22814294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5E84966-1B16-45A1-99B2-12B4FC445CB9</gtr:id><gtr:title>T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34f678584bd9434ddbe82dfdfa39e71a"><gtr:id>34f678584bd9434ddbe82dfdfa39e71a</gtr:id><gtr:otherNames>Marks DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>8A27D88F0F3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C7D3F43-B4FC-4954-94F3-A901AA45DF1C</gtr:id><gtr:title>Cyclin C is a haploinsufficient tumour suppressor.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/866e51b6e22a93cc21d4fa8eeaa1906a"><gtr:id>866e51b6e22a93cc21d4fa8eeaa1906a</gtr:id><gtr:otherNames>Li N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>5464cc8fbb6062.13038815</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500389</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>